Nilssen, Yngvar
Brustugun, Odd Terje
Fjellbirkeland, Lars
Helland, Åslaug
Møller, Bjørn
Wahl, Sissel Gyrid Freim
Solberg, Steinar
Funding for this research was provided by:
University of Oslo
Article History
Received: 11 December 2023
Accepted: 20 February 2024
First Online: 4 March 2024
Declarations
:
: This study has been carried out in accordance with the guidelines in Declaration of Helsinki.
: The transfer of data to the CRN is mandatory by law for all hospitals. No patient contact has been necessary for this study.
: As the Cancer Registry of Norway is statutory, no consent is needed to present data on group basis.
: Steinar Solberg received grant (#212426) from The Norwegian Cancer Society. Åslaug Helland received Research support from AstraZeneca, Roche, Novartis, Incyte, EliLilly, BMS, Ultimovacs, the Norwegian Cancer Society, The regional health authorities in Norway. Have given talks and advise to pharma companies, and all honoraries are going to the hospital (Astra, Roche, Janssen, Novartis, Takeda, Pfizer, BMS, EliLilly, Abbvie, Merck, Sanofi). The other authors declare no conflict of interest.